News

News2021-03-03T16:00:34+00:00
091, 2020

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone – Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for [...]

0821, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, 2020 — Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have [...]

0819, 2020

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering PLYMOUTH MEETING, PA and CHICAGO, IL, August 18, 2020 — Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering [...]

0812, 2020

Paragon Biosciences Appoints Kerensa Jimenez as Paragon Health Capital Chief Executive Officer

Paragon Biosciences Appoints Kerensa Jimenez as Paragon Health Capital Chief Executive Officer Chicago, August 12, 2020 – With strong momentum in its growing portfolio of life science companies, Paragon Biosciences announced the appointment of Kerensa Jimenez as the new chief executive officer of its capital markets group, Paragon Health Capital (PHC), a registered broker-dealer. With [...]

0723, 2020

Synthetic Protein Design and Production Publication Confirms Evozyne’s Revolutionary Technology

Synthetic Protein Design and Production Publication Confirms Evozyne’s Revolutionary Technology Publication in peer-reviewed journal Science demonstrates the foundation of the company’s evolution-based, data-driven engineering technology to build artificial functional enzymes Chicago, July 23, 2020 – A publication released in the peer-review journal Science today demonstrates the foundation of Evozyne’s evolution-based, data-driven engineering process for building [...]

Archives
Go to Top